3192p 6.0 0.2%
Last Trade - 19/02/20
| Market Cap | £2.07bn |
| Enterprise Value | £2.15bn |
| Revenue | £488.5m |
| Position in Universe | 292nd / 1836 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company's segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe. The Genus ABS segment is engaged in bovine sales business, excluding Asia, and serves dairy and beef customers in North America, Latin America and Europe. The Genus Asia segment is engaged in porcine and bovine business in Asia, and serves porcine, dairy and beef customers in Asian markets. In the porcine market, it sells boars and sows. In the dairy and beef markets, its primary product is bull semen. The Company offers embryos through its subsidiary, In Vitro Brasil S.A. Its porcine business has a network of over 600 breeding herds in approximately 40 countries.
| Last Annual | June 30th, 2019 |
| Last Interim | June 30th, 2019 |
| Incorporated | September 26, 1994 |
| Public Since | July 6, 2000 |
| No. of Shareholders: | n/a |
| No. of Employees: | 2,964 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSE 350 , FTSE 350 Lower Yield , FTSE 250 , FTSE 350 Pharmaceuticals & Biotechnology , FTSE Techmark Focus , FTSE Techmark All Share , , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 65,079,864 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Matrix House Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom |
| Web | https://www.genusplc.com |
| Phone | +44 1256 347100 |
| Contact | Charles Ryland (IR Contact Officer) |
| Auditors | Deloitte LLP |
